NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from Skye Peptides? Mail in a sample (US only) and let us test it.

Test my supply
+4 more ↓
57%
Finnrick rating
#461 of 500 ranked vendors
48 of 93 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Skye Peptides has a sharply uneven purity-focus record, with Semaglutide and Tirzepatide testing comparatively strong and Retatrutide more mixed but supported by clean identity checks. BPC-157, Tesamorelin, CJC-1295 and Survodutide show repeated purity misses, while recent volume helps but narrow or missing batch documentation limits confidence.

methodology →
vendor intelligence report
Vendor Intelligence Report: Skye Peptides

Wyoming filings and trademark records trace Skye Peptides through an IP-holding affiliate while the natural-person owner remains unresolved. The report also maps the login gate, GLP-1 COA mismatch, and live copycat domains still causing buyer confusion.

31 pages7 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.98
83%
3
2
Semaglutide
$13.39
78%
9
3
Tirzepatide
$9.60
77%
12
4
Retatrutide
$8.25
72%
13
5
Ipamorelin
$6.69
68%
8
6
Mazdutide
$16.50
62%
5
7
Melanotan II
$4.27
51%
4
8
Survodutide
$16.01
41%
4
9
Tesamorelin
$6.90
40%
8
10
BPC-157
$5.90
40%
17
11
TB-500
$6.90
38%
3
12
CJC-1295
$6.69
29%
7
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%20 May 2025: 47%20 May 2025: 47%20 May 2025: 47%21 May 2025: 46%21 May 2025: 46%21 May 2025: 45%21 May 2025: 45%24 Jul 2025: 42%24 Jul 2025: 44%24 Jul 2025: 44%5 Aug 2025: 44%14 Aug 2025: 44%16 Aug 2025: 44%16 Dec 2025: 45%9 Jan 2026: 46%9 Jan 2026: 47%26 Jan 2026: 49%4 Feb 2026: 49%4 Feb 2026: 50%18 Feb 2026: 50%20 Feb 2026: 51%22 Feb 2026: 51%9 Apr 2026: 52%11 Apr 2026: 56%23 Apr 2026: 56%11 May 2026: 56%27 Aug 2026: 57%27 Aug 2026: 57%27 Aug 2026: 57%27 Aug 2026: 57%27 Aug 2026: 56%31 Aug 2026: 56%31 Aug 2026: 56%31 Aug 2026: 57%15 Sep 2026: 57%16 Sep 2026: 57%16 Sep 2026: 56%16 Sep 2026: 56%21 Sep 2026: 56%29 Sep 2026: 55%17 Nov 2026: current 57%47%45%57%May 25Nov 26
Peptide testing

Ordered peptides from Skye Peptides? Mail in a sample (US only) and let us test it.

Test my supply
Skye Peptides test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
29 Sep 2026
Fail
GHK-Cu
lab nameView COA
21 Sep 2026
Fail
Tesamorelin
lab nameView COA
16 Sep 2026
Fail
Retatrutide
lab nameView COA
16 Sep 2026
Fail
BPC-157
lab nameView COA
16 Sep 2026
Fail
Ipamorelin
lab nameView COA
15 Sep 2026
Pass
BPC-157
lab nameView COA
31 Aug 2026
Pass
Ipamorelin
lab nameView COA
31 Aug 2026
Pass
BPC-157
lab nameView COA
31 Aug 2026
Pass
GHK-Cu
lab nameView COA
27 Aug 2026
Fail
Ipamorelin
lab nameView COA
1-10 of 93

About Skye Peptides test results from Finnrick

Skye Peptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 12 peptides and 93 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Skye Peptides peptides in this dataset are Semaglutide (9 tests) and Melanotan II (4 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 93 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from Skye Peptides? Mail in a sample (US only) and let us test it.

Test my supply